Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Deal Origination Executive Search For Sales Teams Corporate Development For Founders For Agencies For Investors Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Start Free
AceLink Therapeutics logo — Overcome genetic diseases, one at a time

AceLink Therapeutics

Overcome genetic diseases, one at a time

Founded 2019 United States Newark, United States 4 employees Series Unknown

General Information

Company Name AceLink Therapeutics
Founded Year 2019
Location United States Newark, United States +1
Employees 4
Funding Stage Series Unknown
Social

Get notified when AceLink Therapeutics moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About AceLink Therapeutics

AceLink Therapeutics is a biopharmaceutical startup based in the San Francisco Bay Area, founded in 2019. The company's mission is to develop innovative drugs to combat genetically associated human diseases. Their initial focus is on creating a small molecule drug for polycystic kidney disease (PKD), a condition affecting 12 million patients globally. The recent Venture Round investment on 01 January 2022 attracted funding from Viva BioInnovator, Kaitai Capital, and Xiamen Changrong Investment Management. With a commitment to "overcome genetic diseases, one at a time," AceLink Therapeutics demonstrates potential in addressing unmet medical needs.

Taxonomy: biopharmaceutical, startup, drug development, genetic diseases, small molecule drugs, polycystic kidney disease, San Francisco Bay Area, precision medicine

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Venture Round •••••• 3
Investor Investor Investor
01 Jan 2022

AceLink Therapeutics Alternatives & Competitors

AceLink Therapeutics vs
Fibrocor Therapeutics
Fibrocor Therapeutics Canada

Targeting Fibrosis Through the Lens of Disease Progression

11 employees
AceLink Therapeutics vs
Marea Therapeutics
Marea Therapeutics United States

The Next Frontier of Medicines for Cardioendocrine Diseases

42 employees
AceLink Therapeutics vs
ReviR Therapeutics
ReviR Therapeutics United States

Improve human health by Revising drug discovery using RNA and AI technologies

Series A
22 employees
Biotechnology, Health and Wellness

FAQ About AceLink Therapeutics

Overcome genetic diseases, one at a time
AceLink Therapeutics was founded in 2019.
AceLink Therapeutics is headquartered in Newark, United States.
AceLink Therapeutics has approximately 4 employees.
AceLink Therapeutics has completed 1 funding round. The latest funding stage is Series Unknown.
Top alternatives and competitors to AceLink Therapeutics include Fibrocor Therapeutics, Marea Therapeutics, ReviR Therapeutics, Phialogics - The immune tolerance company, CardiaTec Bio. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
AceLink Therapeutics and Fibrocor Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors AceLink Therapeutics and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

Start Tracking — Free

One analytics cookie (Google Analytics). Cookie Policy